Detalhe da pesquisa
1.
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
N Engl J Med
; 379(23): 2220-2229, 2018 12 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30280641
2.
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
N Engl J Med
; 378(24): 2288-2301, 2018 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29863955
3.
Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.
Oncologist
; 24(8): 1095-1102, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30975923
4.
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Lancet Oncol
; 16(3): 257-65, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25704439
5.
Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin.
Mol Cancer
; 10: 35, 2011 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-21470426
6.
Association of patient characteristics with chemotherapy receipt among depressed and non-depressed patients with non-small cell lung cancer.
Psychooncology
; 23(11): 1318-22, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24771684
7.
Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC.
Lung Cancer
; 111: 108-115, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28838379
8.
EGFR Mutations in Latinos From the United States and Latin America.
J Glob Oncol
; 2(5): 259-267, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28717712
9.
Cloning and functional expression of the bovine GABA(C) rho2 subunit. Molecular evidence of a widespread distribution in the CNS.
Neurosci Res
; 53(4): 421-7, 2005 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-16213047
10.
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.
J Clin Oncol
; 33(9): 1000-7, 2015 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-25667274
11.
From platinum compounds to targeted therapies in advanced thoracic malignancies.
Anticancer Res
; 34(1): 477-82, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24403504
12.
A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study.
Clin Cancer Res
; 20(21): 5392-402, 2014 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25189481
13.
HGF Airway Over-expression Leads to Enhanced Pulmonary Vascularization without Induction of VEGF.
Curr Angiogenes
; 1(1): 52-63, 2012 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33564620
14.
Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis.
J Thorac Oncol
; 7(11): 1707-12, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23059774
15.
Neuroendocrine ACTH-producing tumor of the thymus--experience with 12 patients over 25 years.
J Clin Endocrinol Metab
; 97(7): 2223-30, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22508705
16.
Criteria of evidence to move potential chemopreventive agents into late phase clinical trials.
Curr Drug Targets
; 12(13): 1983-8, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21158704
17.
Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.
J Clin Oncol
; 29(15): 2052-9, 2011 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-21502553
18.
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.
Clin Cancer Res
; 17(5): 1190-9, 2011 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21224376
19.
Reply to A. Stenzinger et al.
J Clin Oncol
; 33(25): 2824, 2015 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26169619
20.
Young male with fanconi anemia and EGFR-mutant non-small-cell lung cancer.
J Thorac Oncol
; 9(11): e83-5, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25436812